Clinical trials, triumphs, and tribulations of glucagon receptor antagonists

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1075-1077

  Pearson, MacKenzie J ^a   Unger, Roger H ^a,b   Holland, William L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOMEGLIVANT; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; FIBROBLAST GROWTH FACTOR 21; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; GLUCAGON RECEPTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; GLUCAGON RELEASE; GLUCAGONOMA; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOGENOLYSIS; HUMAN; HYPERGLUCAGONEMIA; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; NONHUMAN; NOTE; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS RESECTION; PHASE 2 CLINICAL TRIAL (TOPIC); RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SIDE EFFECT;

GLUCAGON; HUMANS; RECEPTORS, GLUCAGON;

EID: 84975806532     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dci15-0033     Document Type: Note

References (26)

1. Kazda CM, Ding Y, Kelly RP, et al. Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12-and 24-week phase 2 studies. Diabetes Care 2016;39:1241-1249
2. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922;12:141-146
3. Best CH. Personal communication to R.H. Unger, 1959
4. Kimball CP, Merlin JR. Some precipitation reactions of insulin. J Biol Chem 1923;58:337-348
5. Staub A, Sinn L, Behrens OK. Purification and crystallization of glucagon. J Biol Chem 1955; 214:619-632
6. Berson SA, Yalow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest 1959;38:1996-2016
7. Unger RH, Eisentraut AM, McCALL MS, Keller S, Lanz HC, Madison LL. Glucagon antibodies and their use for immunoassay for glucagon. Proc Soc Exp Biol Med 1959;102:621-623
8. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med 1978;299: 433-436
9. Sasaki H, Rubalcava B, Baetens D, et al. Identification of glucagon in the gastrointestinal tract. J Clin Invest 1975;56:135-145
10. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. Proc Natl Acad Sci USA 2010;107:16009-16012
11. Maruyama H, Hisatomi A, Orci L, Grodsky GM, Unger RH. Insulin within islets is a physiologic glucagon release inhibitor. J Clin Invest 1984;74:2296-2299
12. Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion. Diabetes Obes Metab 2011;13(Suppl. 1):82-88
13. Wang MY, Yan H, Shi Z, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci USA 2015;112:2503-2508
14. Kawamori D, Kulkarni RN. Insulin modulation of glucagon secretion: the role of insulin and other factors in the regulation of glucagon secretion. Islets 2009;1:276-279
15. Kawamori D, Kurpad AJ, Hu J, et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab 2009;9:350-361
16. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol 2011; 12:141-151
17. Sammons MF, Lee EC. Recent progress in the development of small-molecule glucagon receptor antagonists. Bioorg Med Chem Lett 2015;25:4057-4064
18. Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahrén B. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 2014;63:101-110
19. Gu W, Winters KA, Motani AS, et al. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am J Physiol Endocrinol Metab 2010;299:E624-E632
20. Ali S, Lamont BJ, Charron MJ, Drucker DJ. Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. J Clin Invest 2011;121:1917-1929
21. Guan HP, Yang X, Lu K, et al. Glucagon receptor antagonism induces increased cholesterol absorption. J Lipid Res 2015;56:2183-2195
22. Lee Y, Berglund ED, Wang MY, et al. Metabolic manifestations of insulin deficiency do not occur without glucagon action. Proc Natl Acad Sci USA 2012;109:14972-14976
23. Kelly RP, Garhyan P, Raddad E, et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab 2015;17:414-422
24. Rocha DM, Faloona GR, Unger RH. Glucagon-stimulating activity of 20 amino acids in dogs. J Clin Invest 1972;51:2346-2351
25. Solloway MJ, Madjidi A, Gu C, et al. Gluca-gon couples hepatic amino acid catabolism to mTOR-dependent regulation of a-cell mass. Cell Reports 2015;12:495-510
26. Kazda CM, Garhyan P, Ding Y, et al. A euglycemic clamp pilot study assessing the effects of the glucagon receptor antagonist LY2409021 on 24-h insulin requirement in patients with T1DM (Late-breaking Abstract). Diabetes 2013;62 (Suppl. 1):LB18